Back to results

CompletedPhase 2

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

NCT02536742

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Sint-Augustinus

Antwerp, Belgium

+18 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2016-08-30
Enrollment: 124 participants
Sponsor: ETOP IBCSG Partners Foundation
Purpose: treatment

Locations (19)

Sint-AugustinusAntwerp, Belgium
Institut Jules BodetBrussels, Belgium
Cliniques Universitaires Saint-LucBrussels, Belgium
Antwerp University HospitalEdegem, Belgium
UZ LeuvenLeuven, Belgium
CHU LiegeLiège, Belgium
Clinique St. ElizabethNamur, Belgium
Ospedali degli Infermi, S.O.C. OncologiaBiella, Italy
Ospedale Centrale Bolzano, Medical OncologyBolzano, Italy
IRCCS San Martino University HospitalGenova, Italy
Mater Salutis Hospital AULSS 21 della Regione VenetoLegnago, Italy
Istituto Europeo di OncologiaMilan, Italy
Istituti Clinici Scientifici Maugeri, Medical Oncology UnitPavia, Italy
Azienda USL4 PratoPrato, Italy
Velindre NHS TrustCardiff, United Kingdom
Western General HospitalEdinburgh, United Kingdom
Beatson West of Scotland Cancer CentreGlasgow, United Kingdom
Singleton HospitalSwansea, United Kingdom
Royal CornwallTruro, United Kingdom

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer — TrialFind